Pfizer sees promising results from antibiotic combo for superbug infections – National | 24CA News
Pfizer Inc mentioned on Thursday information from late-stage trials confirmed its experimental mixture of antibiotics was efficient in treating lethal infections brought on by drug-resistant micro organism.
Deaths from antibiotic-resistant micro organism, also referred to as superbugs, have been on the rise globally, and well being regulators have known as for the event of newer therapies as resistance to older antibiotics grows.
The late-stage research in contrast the experimental mixture of the antibiotics aztreonam-avibactam (ATM-AVI) and present generic drug metronidazole with a mix of two older antibiotics – meropenem and colistin – to deal with difficult intra-abdominal infections and forms of hospital-acquired pneumonia.
Hospital-acquired pneumonia happens in sufferers at the very least two to 3 days after being admitted, or in those that have life-threatening lung infections with excessive mortality charges and who’re on mechanical respiratory machines.
Pfizer mentioned the info from the research exhibits the antibiotic mixture of ATM-AVI is efficient and well-tolerated in treating infections brought on by gram-negative micro organism.
The remedy price in sufferers with difficult intra-abdominal infections with Pfizer’s mixture remedy, together with present generic drug metronidazole, was 76.4%, versus 74% utilizing the opposite antibiotics.
For sufferers with forms of hospital-acquired pneumonia and ventilator‐related pneumonia, the remedy price was 45.9% for Pfizer’s antibiotic mixture with metronidazole, versus 41.7% for different, older therapies.
The Centers for Disease Control and Prevention estimates that 2.8 million antimicrobial-resistant infections happen annually within the United States.
— Reporting by Leroy Leo and Sriparna Roy in Bengaluru; Editing by Pooja Desai
© 2023 Thomson Reuters
